Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Refractory Colorectal Carcinoma: early-phase trial registry
A small indexed set (5 trials) with no open enrollment listed right now.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · none currently recruiting · #3,391 of 28,707 conditions by registered trial count
Refractory Colorectal Carcinoma: 5 US clinical trials tracked, none currently recruiting.
Refractory Colorectal Carcinoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition refractory-colorectal-carcinoma
OPEN 0 | RECR 0% | LATE 0 | EARLY 5 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Refractory Colorectal Carcinoma has no open enrollment in this registry pull (5 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Refractory Colorectal Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Refractory Colorectal Carcinoma is recruiting below its size-band peers.
0 of 5 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Refractory Colorectal Carcinoma research.
M.D. Anderson Cancer Center accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Refractory Colorectal Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 66 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.
-
Refractory Colorectal Carcinoma research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
NCT03844620
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT02595931
TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer
Rutgers, The State University of New Jersey
NCT04294264
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
M.D. Anderson Cancer Center
NCT02983578
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
Academic and Community Cancer Research United
NCT02873195
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Refractory Colorectal Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Refractory Colorectal Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Refractory Colorectal Carcinoma page
5 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Refractory Colorectal Carcinoma trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- M.D. Anderson Cancer Center sponsors the most Refractory Colorectal Carcinoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Colorectal Carcinoma condition card totals 5 registered trials; most-linked intervention Laboratory Procedure; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.